Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11381058 | 0.82 | KMT2A (0.56) | CYP2D6 | |
| SCHEMBL21667937 | 0.80 | MAPK1 (0.50) | — | |
| SCHEMBL25609819 | 0.80 | MAPK1 (0.50) | — | |
| SCHEMBL21743149 | 0.80 | MAPK1 (0.50) | — | |
| SCHEMBL8962578 | 0.80 | CYP2D6 (0.53) | CYP2D6 | |
| SCHEMBL3066938 | 0.80 | — | — | |
| SCHEMBL9645566 | 0.78 | HTT (0.59) | — | |
| Hydrochloric Acid SCHEMBL10550374 | 0.78 | — | — | |
| SCHEMBL7348336 | 0.78 | CYP2D6 (0.51) | CYP2D6 | |
| SCHEMBL7063746 | 0.78 | CYP2D6 (0.48) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022140621-A1 | CHEMICALLY HOMOGENEOUS SILICON HARDMASKS FOR LITHOGRAPHY | BREWER SCIENCE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-9926290-B2 | Inhibitors of INV(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926290-B2 | Inhibitors of INV(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2016-04-07 | — | — | US | disclosed |
| US-9221764-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140243331-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-8748618-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-03-08 | — | — | US | disclosed |
| US-20110077237-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | CYP2D6 3113/4885 |
| US-20120214799-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | CYP2D6 3113/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | CYP2D6 3113/4885 |
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | CYP2D6 3481/4885 |
| US-20140243331-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | CYP2D6 3492/4885 |
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | CYP2D6 3492/4885 |
| US-20110077237-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | CYP2D6 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.